Oncolytic HSV and PI3K inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells.

被引：0
|
作者：
Wang, Lei [1 ]
机构：
[1] Wuhan Univ, Zhongnan Hosp, Wuhan, Hubei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e16503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16503
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells
    Hu, Y.
    Guo, R.
    Wei, J.
    Zhou, Y.
    Ji, W.
    Liu, J.
    Zhi, X.
    Zhang, J.
    CELL DEATH & DISEASE, 2015, 6 : e2020 - e2020
  • [22] Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells
    Y Hu
    R Guo
    J Wei
    Y Zhou
    W Ji
    J Liu
    X Zhi
    J Zhang
    Cell Death & Disease, 2015, 6 : e2020 - e2020
  • [23] The effect combining the KIT inhibitor Imatinib with the PI3K inhibitor BKM120 or the dual PI3K/mTOR inhibitor BEZ235 on the proliferation of gastrointestinal stromal tumor cell lines
    Li, Fang
    Growney, Joseph
    Battalagine, Linda
    Qiu, Shumei
    Manley, Paul
    Monahan, John
    CANCER RESEARCH, 2012, 72
  • [24] Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120
    Bashash, Davood
    Delshad, Mahda
    Safaroghli-Azar, Ava
    Safa, Majid
    Momeny, Majid
    Ghaffari, Seyed H.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2017, 91 : 1 - 8
  • [25] Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO)
    Alipour, Faranak
    Riyahi, Niknam
    Safaroghli-Azar, Ava
    Sari, Soyar
    Zandi, Zahra
    Bashash, Davood
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2019, 116
  • [26] Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas
    Anderson, Jennifer L.
    Park, Ann
    Akiyama, Ryan
    Tap, William D.
    Denny, Christopher T.
    Federman, Noah
    PLOS ONE, 2015, 10 (09):
  • [27] Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC)
    Saura, C.
    Burris, H.
    Arteaga, C. L.
    Mayer, I.
    Germa, C.
    Fretault, N.
    Sternberg, D.
    Trandafir, L.
    Massacesi, C.
    Rodon, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S96 - S96
  • [28] Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120
    Bashash, Davood
    Delshad, Mahda
    Riyahi, Niknam
    Safaroghli-Azar, Ava
    Pourbagheri-Sigaroodi, Atieh B.
    Momeny, Majid
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2018, 841 : 10 - 18
  • [29] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Ana C. Garrido-Castro
    Cristina Saura
    Romualdo Barroso-Sousa
    Hao Guo
    Eva Ciruelos
    Begoña Bermejo
    Joaquin Gavilá
    Violeta Serra
    Aleix Prat
    Laia Paré
    Pamela Céliz
    Patricia Villagrasa
    Yisheng Li
    Jennifer Savoie
    Zhan Xu
    Carlos L. Arteaga
    Ian E. Krop
    David B. Solit
    Gordon B. Mills
    Lewis C. Cantley
    Eric P. Winer
    Nancy U. Lin
    Jordi Rodon
    Breast Cancer Research, 22
  • [30] Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Saura, Cristina
    Barroso-Sousa, Romualdo
    Guo, Hao
    Ciruelos, Eva
    Bermejo, Begona
    Gavila, Joaquin
    Serra, Violeta
    Prat, Aleix
    Pare, Laia
    Celiz, Pamela
    Villagrasa, Patricia
    Li, Yisheng
    Savoie, Jennifer
    Xu, Zhan
    Arteaga, Carlos L.
    Krop, Ian E.
    Solit, David B.
    Mills, Gordon B.
    Cantley, Lewis C.
    Winer, Eric P.
    Lin, Nancy U.
    Rodon, Jordi
    BREAST CANCER RESEARCH, 2020, 22 (01)
12345